EOG Resources completes $5.6 billion acquisition of Encino Acquisition Partners
Nicholas B. Hawkins (NASDAQ:HWKN), the Vice President and Chief Financial Officer of Arteris , Inc. (NASDAQ:AIP), recently executed a series of stock sales, according to a filing with the Securities and Exchange Commission. On April 2, 2025, Hawkins sold a total of 3,888 shares of Arteris common stock at an average price of $7.1186 per share, totaling approximately $27,677. The sales come as the stock has declined over 41% year-to-date, with InvestingPro data showing the stock trading near its 52-week low of $5.76.
Subsequently, on April 4, 2025, Hawkins sold an additional 4,949 shares at a weighted average price of $6.026 per share, amounting to roughly $29,822. This transaction was conducted under a 10b5-1 trading plan, which Hawkins adopted on May 20, 2024. Despite recent price weakness, Arteris maintains impressive gross profit margins of nearly 90%, according to InvestingPro analysis, which offers 8 additional key insights about the company’s financial health and valuation.
These sales were partly made to satisfy Hawkins’s tax obligations arising from the release of restricted stock units. Following these transactions, Hawkins retains ownership of 176,596 shares of Arteris common stock, representing a significant stake in the company, which currently has a market capitalization of $270 million.
In other recent news, Arteris, Inc. reported revenue that met expectations for the quarter, with guidance aligning with forecasts. Northland analysts responded by raising their price target for Arteris shares from $14.00 to $16.00, maintaining an Outperform rating. The company’s bookings reached approximately $33.6 million, with a book-to-bill ratio of 2.2:1, highlighting strong momentum in new product introductions. Meanwhile, Jefferies adjusted its price target for Arteris from $7.00 to $11.00, maintaining a Hold rating, due to recent progress in the microcontroller unit market and the introduction of the FlexGen solution, which is expected to increase average selling prices by 30%.
Arteris’ new FlexGen product has generated interest, with 13 customers currently evaluating it, suggesting a potential for future revenue growth. Northland analysts noted the success of the company’s FlexNoC 5 product, which accounted for three-quarters of all interconnect licenses during the period. In corporate governance news, Arteris announced the resignation of board member Isabelle F. Geday, effective March 27, 2025, due to personal reasons unrelated to company disagreements. The board approved the accelerated vesting of her 19,287 restricted stock units, originally set to vest later in 2025. These developments reflect Arteris’ evolving strategic position in the competitive semiconductor industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.